LambdaVision

Farmington, United States Founded: 2009 • Age: 17 yrs
Protein-based retinal prosthesis for degenerative eye diseases is provided.

About LambdaVision

LambdaVision is a Healthcare company based in Farmington (United States) founded in 2009. Protein-based retinal prosthesis for degenerative eye diseases is provided. LambdaVision has raised $7.65 million across 10 funding rounds from investors including NASA, HHS and Boryung Pharmaceutical. The company has 7 employees. LambdaVision offers products and services including Protein-based Artificial Retina. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is LambdaVision, Inc. Its competitors include Rezolute, Aviceda Therapeutics and EyePoint Pharmaceuticals; 1 of its 3 listed competitors has raised funding.

Company details

LambdaVision was founded in 2009 in Farmington, United States, within the biotechnology sector focused on medical devices. A protein-based retinal prosthesis is developed by the company to address retinal degenerative diseases such as age-related macular degeneration and retinitis pigmentosa. Photochemical properties of retinylidene proteins are utilized to enable high-resolution vision restoration. Operations center on improving patient quality of life through this innovative approach.

Key Metrics
  • Total Equity Funding
    $7.65M (USD)

    in 10 rounds

  • Latest Funding Round
    $7M (USD), Seed

    Nov 2025

  • Investors
    NASA

    & 8 more

  • Employee Count
    7

Products & Services of LambdaVision

LambdaVision offers a comprehensive portfolio of products and services, including Protein-based Artificial Retina.

Protein-based Artificial Retina
Medical Device

Restores vision by mimicking photoreceptors in retinal diseases.

Funding Insights of LambdaVision

LambdaVision has successfully raised a total of $7.65M across 10 strategic funding rounds. The most recent funding activity was a Seed round of $7 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $7.65M
  • Total Rounds 10
  • Last Round Seed — $7M
  • First Round $40,000

    (Oct 2011)

  • Investors Count 9

All 10 funding rounds of LambdaVision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2025$7MSeed–Seven Seven Six
–
May 2024Series A–Aurelia Foundry
Sep 2020Grant––
Oct 2017$500,000Series A––
Nov 2016Grant––
Sep 2016$1.04MGrant––
Jan 2015$179,937Grant––
Sep 2014$170,662Grant––
May 2013$110,000Seed––
Oct 2011$40,000Seed––
Valuation history

9 investors in total: 9 institutional.

Investors in LambdaVision

LambdaVision has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NASA, HHS and Boryung Pharmaceutical.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm investing in tech sectors
e2mc.spaceOrlando, United States
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
ctinnovations.com
Early-stage entrepreneurs are accelerated through MassChallenge's program.
masschallenge.orgBoston, United States
Venture capital fund backed by the US Government
seedfund.nsf.govAlexandria, United States
Venture capital fund focused on investing in technology startups
sevensevensix.com
Finished formulations and APIs are developed for diverse disease areas.
1963boryung.co.krSeoul, South Korea
Invests in and incubates startups focused on space, AI, and climate technologies.
2023aureliafoundry.comWellesley, United States
Government space exploration and research services are provided.
1958nasa.govUnited States
Public health and human services are overseen by HHS.
1953hhs.gov
Premium access

Investor details for LambdaVision

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of LambdaVision

7 people are tracked at LambdaVision (3 in leadership, 4 in board & advisors); the tracked headcount is 7.

NameRoleGroup
Nicole L. Wagner
President & CEOLeadership
Jordan A. Greco
Chief Scientific OfficerLeadership
Jordan Greco, Ph.D.
Chief Scientific OfficerLeadership
Susan Froshauer
DirectorBoard & advisors
Robert R. Birge
FounderBoard & advisors
Pauline Murphy
DirectorBoard & advisors
Kirk Dornbush
DirectorBoard & advisors
Premium access

Complete people profiles for LambdaVision

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of LambdaVision

3 dated milestones of LambdaVision across 16 years, from founding to its latest funding, stage changes and deals.

  1. Founded LambdaVision is founded.
  2. Funding First funding round of $40K.
  3. Funding Latest funding round, Seed, of $7.0M.

Competitors of LambdaVision

LambdaVision has 3 listed competitors in our database, 1 of them funded. They include Rezolute, Aviceda Therapeutics and EyePoint Pharmaceuticals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
rezolutebio.com2012Denver, United States51
Therapies for metabolic and orphan diseases are developed by Rezolute.
avicedarx.com2018Cambridge, United States$254.66M
Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas.
eyepointpharma.com1987Watertown, United States49
Small molecule therapeutics for ophthalmic disorders are developed.
Premium access

Detailed competitors of LambdaVision

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of LambdaVision

The website of LambdaVision (lambdavision.com) receives about 2.5K visits a month.

  • Monthly visits
    2.5K

    ▼ 2.5% vs previous month

Similar websites

Websites whose visitors overlap most with LambdaVision. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
facebook.com
100%
12.1B#3View details

Top companies in Ophthalmology

3 companies that operate in the same segment as LambdaVision (Ophthalmology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of a wide range of eye care products
1945Fort Worth, Texas, United StatesUSD 171.61 MUSD 24.69 B25,941
Genetic medicines are developed by 4DMT for transformative therapies.
2013Emeryville, California, United StatesUSD 186.59 MUSD 85.21 M227
Developer of antibodies to treat complement-mediated neurodegenerative diseases
2011San Francisco, California, United StatesUSD 256 M100
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Lambdavision

Premium access

Complete news archive for LambdaVision

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about LambdaVision

LambdaVision was founded in 2009 and raised its 1st funding round 2 years after it was founded.

LambdaVision is headquartered in Farmington, United States.

LambdaVision is a funded company, having raised a total of $7.65M across 10 funding rounds to date. The company's 1st funding round was a Seed of $40K, raised on Oct 2011.

LambdaVision has 7 employees.

LambdaVision was founded in 2009 in Farmington, United States, within the biotechnology sector focused on medical devices. A protein-based retinal prosthesis is developed by the company to address retinal degenerative diseases such as age-related macular degeneration and retinitis pigmentosa. Photochemical properties of retinylidene proteins are utilized to enable high-resolution vision restoration. Operations center on improving patient quality of life through this innovative approach.

LambdaVision's top competitors include EyePoint Pharmaceuticals, Rezolute and Aviceda Therapeutics.

LambdaVision offers Protein-based Artificial Retina.

LambdaVision has 9 investors. Key investors include NASA, HHS, Boryung Pharmaceutical, E2MC, and Aurelia Foundry.

LambdaVision operates through Lambdavision, Inc.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available